ISDS Case Map
medicines
India - UK FTA provisions favor neither India nor the UK except the pharma industry in a big way. It defeats the firm stand taken by the Indian PM three years ago when he decided to pull out of the RCEP against the corporate interests over people’s lives.
UK IP demands contain provisions that would drastically harm access to affordable, lifesaving generic medicines from India, upon which millions of people around the world rely.
Consolidated negotiating COVID intellectual property text as of 25/5/2022
After the Comprehensive Economic Cooperation Agreement signed between India and Australia, the domestic pharmaceutical industry is seeing a plethora of opportunities for international trade.
On farmers and food, vaccine inequality, climate justice and digital rights, we need to act in solidarity – and not allow trade rules to sacrifice people to corporate profit.
Even without an IP waiver from the WTO, China and India are leading the challenge to the West’s vaccine monopoly.
Talks on a possible COVID-19-related TRIPS decision aimed at scaling up vaccine and therapeutics production and equitable distribution continue but investment agreements are absent from them.
There is evidence of a potential conflict between the CPTPP and the UK’s current system of market authorisation of generic and biosimilar drugs.
Heesob Nam, a patent attorney who dedicated his life to preventing the monopoly of 'intellectual property' by a few, passed away on May 10th.
The patent waiver initiative may give rise to claims under the expropriation standard, and to a lesser degree, under the FET standard.
